HQL News and Press, TeklaLife Sciences Investors From 06/21/19

By Andy Acker, CFA and Denny Fish Portfolio Managers Andy Acker and Denny Fish explore disruptive forces in healthcare and technology. Disruption is being felt across industries and geographies and proving to be a differentiator in the long-term performance of investors' portfolios. Su...

This article was first released to CEF/ETF Income Laboratory subscribers 2 weeks ago, so data may be out of date. Please check latest data before making investment decisions. The Weekly Closed-End Fund Roundup will be put out at the start of each week to summarize recent price moveme...

Array BioPharma is  up 56%  after agreeing to a sale to Pfizer for more than $10B. UniQuire, meanwhile, is  higher by 8.35%  after a weekend report that it's exploring a sale. More news on: BioMarin Pharmaceutical Inc., bluebird bio, Inc., Sage Therapeutics, Inc., H...

By Tony DeSpirito Markets tend to focus on one risk at a time, and it’s fragile U.S.-China relations that are front and center now. New blog contributor Tony DeSpirito offers up two potential takeaways for equity investors. Headlines over the U.S.-China trade dispute have been p...

This article was first released to CEF/ETF Income Laboratory subscribers two weeks ago, so data may be out of date. Please check latest data before making investment decisions. The Weekly Closed-End Fund Roundup will be put out at the start of each week to summarize recent price...

This article was first released to CEF/ETF Income Laboratory subscribers 2 weeks ago, so data may be out of date. Please check latest data before making investment decisions. Quantitative screens help to rapidly narrow down attractive candidates from the database of 500-plus closed-end ...

For a while now, I have been on the lookout for a good technology-focused closed-end fund. Admittedly, this is something of a rare breed as most closed-end funds are focused on the generation of income, and technology stocks are generally considered to be growth investments. These stocks, part...

This article was first released to CEF/ETF Income Laboratory subscribers 1 month ago, so data may be out of date. Please check latest data before making investment decisions. Quantitative screens help to rapidly narrow down attractive candidates from the database of 500-plus closed-end ...

This article was first released to CEF/ETF Income Laboratory subscribers 2 weeks ago, so data may be out of date. Please check latest data before making investment decisions. The Weekly Closed-End Fund Roundup will be put out at the start of each week to summarize recent price movement...

For income investors, closed-end funds, or CEFs, are an attractive class of asset that promises high income generally in the range of 6%-10%, broad diversification in terms of types of assets, and market matching total returns in the long term, if selected carefully. However, CEFs come with ...